In vitro influence of metronidazole on the activities of ciprofloxacin against clinically important bacterial isolates

Morenike Olutumbi Adeoye-Isijola; Babasola Adewunmi Osopale; Olufunmiso Olusola Olajuyigbe

doi:10.30574/gscbps.2019.6.3.0006

Authors

Morenike Olutumbi Adeoye-Isijola Department of Microbiology, School of Science and Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
Babasola Adewunmi Osopale Department of Microbiology, School of Science and Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.
Olufunmiso Olusola Olajuyigbe Department of Microbiology, School of Science and Technology, Babcock University, PMB 4005, Ilisan-Remo, Ogun State, Nigeria.

DOI:

https://doi.org/10.30574/gscbps.2019.6.3.0006

Keywords:

Antibiotics, Bacterial infections, Drug-drug interactions, Synergism, Additive interaction

Abstract

A continued in vitro investigation into drug-drug interaction is necessary to avert dangerous drug combinations and achieve effective therapy at lower drug concentrations. In this study, the interactions of ciprofloxacin and metronidazole and the effectiveness of the antibacterial combinations against selected bacterial strains were investigated by agar diffusion, macrobroth dilution and the checkerboard assay methods. The results showed that the combined antibiotics had better antibacterial effects than those produced by the ciprofloxacin while no inhibition zone was produced by metronidazole at the concentrations used. At the highest concentration of the combination, the inhibition zones ranged between 28±1.00 mm and 37±1.00 mm while Plesiomonas shigelloidis was highly resistant. While the minimum inhibitory concentrations (MICs) of ciprofloxacin ranged between 0.05 and 3.13 µg/ml and those of metronidazole were between 15.63 and 62.5 µg/ml, the MICs for the antibacterial combinations were between 0.02/0.12 and 3.13/1.56 (Cip/Met) µg/ml against all the test microorganisms. The percentage reduction in the MICs showed that while the MICs of ciprofloxacin were reduced by between 0 and 96.87%, those of metronidazole were reduced by between 0 and 99.80 % when the two antibiotics were combined. The interaction of ciprofloxacin and metronidazole was more of synergy (55.56 %) than additive/indifference (44.4%). The FICI indicating synergistic interaction ranged between 0.035 and 0.375, the FICI indicating additive/indifference interactions ranged between 0.532 and 1.25. No antagonistic interaction was recorded. The lack of antagonism between these antibacterial agents suggested that their combination would be an improved therapy over the use of each antibiotic individually and may be useful in attaining better therapeutic effects in infections where polymicrobial and resistant bacterial strains may be involved.

Metrics

Metrics Loading ...

References

Coates A, Hu Y, Bax R and Page C. (2002). The future challenges facing the development of new antimicrobial drugs. Nature Reviews Drug Discovery, 1, 895-910.

Krishnan A. (2007). Dictionary of Microbiology, (student edition), Chopsani Road, Jodhpur, 28.

Esposito S and Leone S. (2007). Antimicrobial treatment for intensive care unit (ICU) infections including the role of the infectious diseases specialist. International Journal of Antimicrobial Agents, 29, 494–500.

Lockhart SR, Abramson MA, Beekman SE, Gallagher G, Riedel SR, Diekma DJ, Quinn JP and Doern GV. (2007). Antimicrobial resistance among Gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004. Journal of Clinical Microbiology, 45, 3352–3359.

Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG, Tino MD, Pompliano DL, Tally F, Tipirneni P, Tillotson GS, Powers JH and Tillotson GS. (2007). Anti-infective research and development problems, challenges and solutions: the clinical practitioner perspective. Lancet Infectious Diseases, 7, 68–78.

Zhanel GG, Laing NM, Nichol KA, Palatnick LP, Noreddin A, Hisanaga T, Johnson JL, the NAVRESS group and Hoban DJ. (2003). Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North America Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). Journal of Antimicrobial Chemotherapy, 52, 382–388.

Raymond J and Aujard Y. (2000). Nosocomial infections in pediatric patients: a European multicenter prospective study. European Study Group. Infection Control & Hospital Epidemiology, 21, 260–263.

Schafer JJ, Goff DA, Stevenson KB and Mangino JE. (2007). Early experience with tigecycline for ventilator associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy, 27, 980–987.

Fulton MM and Allen ER. (2005). Polypharmacy in elderly: a literature review. Journal of the American Association of Nurse Practitioners, 17(4),123–32.

Hajjar ER, Cafiero AC and Hanlon JT. (2007). Polypharmacy in elderly patients. The American Journal of Geriatric Pharmacotherapy, 5(4), 345–51.

Chait R, Craney A and Kishony R. (2007). Antibiotic interactions that select against resistance. Nature, 446, 668–671.

Hegreness M, Shoresh N, Damian D, Hartl D and Kishony R. (2008). Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences, USA, 105, 13977–13981.

Michel JB, Yeh P, Chait R, Moellering RC and Kishony R. (2008). Drug interactions modulate the potential for evolution of resistance. Proceedings of the National Academy of Sciences, USA, 105, 14918–14923.

Phillips PC, Otto SP and Whitlock MC. (2000) Epistasis and the Evolutionary Process. Oxford Univ. Press; New York.

Mani R, Onge RPS, Hartman JL, Giaever G and Roth FP. (2008). Defining genetic interaction. Proceedings of the National Academy of Sciences, USA, 105, 3461–3466.

Rybak MJ and McGrath BJ. (1996). Combination antimicrobial therapy for bacterial infections. Guidelines for the Clinician. Drugs, 52, 390–405.

Rosholm JU, Bjerrum L, Hallas J, Worm J and Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly: a prescription database study. Danish Medical Bulletin, 45, 210-213.

Seymour RM and Routledge PA. (1998). Important drug-drug interactions in the elderly. Drugs Aging, 12, 485-494.

Simonson W and Feinberg JL. (2005). Medication-related problems in the elderly. Defining the issues and identifying solutions. Drugs Aging, 22(7), 559–69.

Kuijpers MA, van Marum RJ, Egberts AC and Jansen PA. (2008). Relationship between polypharmacy and under-prescribing. British Journal of Clinical Pharmacology, 65(1), 130–3.

Milton JC, Hill-Smith I and Jackson SHD. (2008). Prescribing for older people. BMJ, 336(7644), 606–9.

Boyle N, Naganathan V and Cumming RG. (2010). Medication and falls: risk and optimization. Clin Geriatr Med, 26(4), 583–605.

Olajuyigbe OO, Oyedeji O and Adedayo O. (2014). Evaluation of the in vitro interaction of amoxicillin and cotrimoxazole antibiotics against resistant bacterial strains. Journal of Applied Pharmaceutical Science, 4(1), 94-100.

Guzey C and Spigset O. (2002). Genotyping of drug targets: a method to predict adverse drug reactions? Drug Safety, 25, 553-560.

Roberts RL, Begg EJ, Joyce PR and Kennedy MA. (2002). How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing. New Zealand Medical Journal, 115, 137-140.

Richard S, Lynn SM and Avery CG. (2007). Antimicrobial susceptibility testing protocols. New York: CRC Press.

Cheesbrough M. (2002). Medical Laboratory Manual for Tropical Countries, ELBS ed; Tropical health technology publications and Butterworth–Heinemann Ltd: Cambridge, UK, 2, 2–392.

Clinical and Laboratory Standard Institute (CLSI). (2008). Performance standards for Antimicrobial Susceptibility Testing Eighteenth informational supplement. M100-S18 2008, 28(1), 46–52.

Kelly DJ. (1992). Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. Journal of infectious Diseases, 166, 1184-7.

Cheesbrough M. (2006). District Laboratory Practice in Tropical Countries. 1st Edn., Cambridge University Press, Cambridge, UK., ISBN-10: 0521665450, 434.

Petersen PJ, Labthavikul P, Jones CH and Bradford PA. (2006). In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. Journal of Antimicrobial Chemotherapy, 57, 573-576.

Mandal S, Mandal MD and Pal NK. (2004). Evaluation of combination effect of ciprofloxacin and cefazolin against Salmonella enteric serovar typhi isolates by in vitro methods. Calicut Medical Journal, 2(2), e2.

Wright GD, (2010). Antibiotic resistance in the environment: a link to the clinic? Microbiology, 13, 589-594.

Hogberg LD, Heddini A and Cars O. (2010). The global need for effective antibiotics: challenges and recent advances. Trends in Pharmacological Sciences, 31, 509–515.

Sosa AJ, Byarugaba DK, Amábile-Cuevas CF, Hsueh P.R, Kariuki S and Okeke IN (eds). (2010). Antimicrobial Resistance in Developing Countries. New York: Springer.

Eisenberg JNS, Goldstick J, Cevallos W, Trueba G, Levy K, Scott J, Percha B, Segovia R, Ponce K, Hubbard A, Marrs C. (2011). In-roads to the spread of antibiotic resistance: regional patterns of microbial transmission in northern coastal Ecuador. Journal of the Royal Society Interface, 9(70), 1029-1039.

Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short Iii GF, Staunton JE, Jin X, Lee MS. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature biotechnology, 27(7), 659–666.

Farha MA and Brown ED. (2010). Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. Chemistry & Biology, 17, 852–862.

Gorbach SL. (1994). Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Medicine, 20 Suppl 3, S27–34.

Alou L, Cafini F, Sevillano D, Unzueta I and Prieto J. (2004). In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin. International Journal of Antimicrobial Agents, 23, 513–6.

Jacqueline C, Navas D, Batard E et al.. (2005). In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin resistant Staphylococcus aureus. Antimicrobial Agents Chemotherapy, 49, 45–51.

Marr KA, Boeckh M, Carter RA, Kim HW and Corey L. (2004). Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases, 39, 797–802.

Azmi AS, Wang Z, Philip PA, Mohammad RM and Sarkar FH. (2010). Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations. Molecular Cancer Therapeutics, 9, 3137–3144.

Glickman MS and Sawyers CL. (2012). Converting cancer therapies into cures: Lessons from infectious diseases. Cell, 148, 1089–1098.

Olajuyigbe OO, Coopoosamy RM and Afolayan AJ. (2017). Effects and time-kill assessment of Amoxicillin in combination with Chloramphenicol against bacteria of clinical importance. Acta Biochimica Polonica, 64(11), 1-5.

Fitzgerald JB, Schoeberl B, Nielsen UB and Sorger PK. (2006). System biology and combination therapy in the quest for clinical efficacy. Nature Chemical Biology, 2, 458–466.

Lehár J, Stockwell BR, Giaever G and Nislow C. (2008). Combination chemical genetics. Nature Chemical Biology, 4, 674–681.

Petri WAJ. (2005). Antimicrobial agents: sulphonamides, trimethoprim-sulfmethaxozole, quinolones, and agents for urinary tract infections. Goodman and Gilman’s The Pharmocol basis of Ther, 10, 1111-1126.

Diniz CG, Santos SG, Pestana AC, Farias LM, Carvalho MA, Auxiliadora M. (2000). Chromosomal breakage in the Bacillus fragilis group induced by metronidazole treatment. Anaerobe, 6, 149–53.

Chen YH, Ko WC and Hsueh PR. (2013). Emerging resistance problems and future perspective in pharmacotherapy. Expert Opinion on Pharmacotherapy, 14, 587-596.

Eagle H and Musselman AD. (1948). The rate of bactericidal action of penicillin in vitro as a function of its concentration and its paradoxically reduced activity at high concentrations against certain organisms. The Journal of Experimental Medicine, 88, 99–131

Lewin CS, Morrissey I and Smith JT. (1991). The mode of action of quinolones: the paradox inactivity of low and high concentrations and activity in the anaerobic environment. European Journal of Clinical Microbiology & Infectious Diseases, 10, 240–248.

Anderson ET, Young LS and Hewitt WL. (1978). Antimicrobial synergism in therapy of Gram Negative Rod Bacteremia. Chemotherapy, 24(1), 45-54.

Dejongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, et al. (1986). Antibiotic Synergism and Response in Gram-Negative Bacteremia in Granulocytopenic Cancer - Patients. The American Journal of Medicine, 80, 96–100.